Shanghai Fosun And Chindex CEO Team Up To Capitalize On China’s Growing Private Markets
This article was originally published in PharmAsia News
Executive Summary
As China opens up its private hospital market and a new wave of investment, major players such as Chindex International Inc. are reevaluating and repositioning themselves to benefit from the growing private infrastructure.
You may also be interested in...
China's Largest Private Pharma Company Fosun Pharma Targets Biosimilar Market, With Sights On Becoming The Next Teva
SHANGHAI - China's largest private integrated healthcare company Shanghai Fosun Pharmaceutical Co. Ltd. will focus on gaining more market share in China with its branded generic business and branded traditional Chinese medicines, the company said during China's first ever Biotechnology Industry Organization conference held in Shanghai
Pricing Pressures Lower Profits For Chinese Drug Chain Nepstar, While Healthcare Reform Has Opposite Effect On Hospital Chain Chindex - China Earnings Roundup (Part 1)
Year-end and Q4 earnings results for Chinese healthcare operators and drug stores are shaped by a challenging environment imposed by China's healthcare reform and increasing drug pricing pressure. In 2010, a rising tide of inflation also increased minimum wages and labor costs across the country and impacted companies' bottom lines. Many firms have resorted to business diversification, innovation and enriched pipelines to sustain a strong growth.
Riding High And Scaling Up, Chindex Readies Business Model Rollout In China
American hospital operator and medical device distributor Chindex is riding strong midterm growth momentum built on its strong branding in China and will likely benefit hugely from China's healthcare reforms and growing middle class.